Patents Assigned to Vivus, Inc.
-
Publication number: 20110262535Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.Type: ApplicationFiled: July 1, 2011Publication date: October 27, 2011Applicant: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Publication number: 20110224196Abstract: This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil, eszopiclone, zolpidem, zaleplon, and phentermine.Type: ApplicationFiled: January 7, 2011Publication date: September 15, 2011Applicant: Vivus, Inc.Inventors: Leland F. Wilson, Peter Tam, Thomas Najarian, Charles H. Bowden
-
Publication number: 20110119597Abstract: Methods and systems are disclosed for enabling participants to interact remotely through multiple multimedia channels based on the configured capabilities of participants. The system consists of a server and one or more client devices. On joining new interactive session, the attributes and capabilities of the participant are determined. Other participants are notified as to the attributes and capabilities of the new participant. The interaction between participants is determined by their attributes and capabilities and that of the participant they wish to interact with. Participants can use a client device to join a session. If the device is capable of rendering a graphical display based on the capability information configured for that participant and device, participants can view multiple views rendered for the session in different regions of a display.Type: ApplicationFiled: May 9, 2010Publication date: May 19, 2011Applicant: ViVu, Inc.Inventors: SivaKiran Venkata Yellamraju, Tandav Krishna Sanka
-
Publication number: 20110022705Abstract: A method or system for enabling client devices connected to a network to subscribe to a one or more multimedia signals available in a selection of bandwidths, based on an analysis of capabilities of the client, the quality of the connection, and the real-time changes in the ability of the client to process the signal.Type: ApplicationFiled: July 20, 2010Publication date: January 27, 2011Applicant: Vivu, IncInventors: SivaKiran Venkata Yellamraju, Simha Sundeep Reddy Katasani
-
Publication number: 20100087402Abstract: The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects.Type: ApplicationFiled: September 29, 2009Publication date: April 8, 2010Applicant: Vivus, Inc.Inventors: Changjin Wang, Leland F. Wilson
-
Patent number: 7674776Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: GrantFiled: March 20, 2006Date of Patent: March 9, 2010Assignee: Vivus, Inc.Inventor: Thomas Najarian
-
Patent number: 7659256Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: GrantFiled: March 20, 2006Date of Patent: February 9, 2010Assignee: Vivus, Inc.Inventor: Thomas Najarian
-
Patent number: 7553818Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: GrantFiled: March 20, 2006Date of Patent: June 30, 2009Assignee: Vivus, Inc.Inventor: Thomas Najarian
-
Publication number: 20090129479Abstract: Methods and apparatus for generating an interactive video stream from a plurality of multimedia components based on a state definition is disclosed. A plurality of multimedia components are retrieved in accordance with the state definition. The plurality of multimedia components are decoded. The plurality of multimedia components are retimed to a common frame rate. The multimedia components are then scaled and multiplexed into a multiplexed video stream, in accordance with the state definition.Type: ApplicationFiled: November 20, 2008Publication date: May 21, 2009Applicant: VIVU, INC.Inventor: SivaKiran Venkata Yellamraju
-
Publication number: 20080227749Abstract: A method is provided for treating a female individual who suffers from or is prone to dyspareunia. The method involves vaginal and/or vulvar administration of a formulation comprising a therapeutically effective amount of a carrageenan and a pharmaceutically acceptable aqueous carrier. In addition, a carrageenan-based formulation is provided as a new composition of matter. Packaged kits for an individual to use in the administration of a carrageenan-based formulation as provided as well.Type: ApplicationFiled: March 31, 2008Publication date: September 18, 2008Applicant: VIVUS, INC.Inventors: Virgil A. Place, Leland F. Wilson
-
Patent number: 7226910Abstract: Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal potypeptide (VIP) and VIP agonists is administered to the vagina and/or vulvar region of the individual undergoing treatment. The formulations are also useful for improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. Pharmaceutical formulations and kits are also provided.Type: GrantFiled: October 28, 2005Date of Patent: June 5, 2007Assignee: Vivus, Inc.Inventors: Leland F. Wilson, Virgil A. Place
-
Publication number: 20060234950Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: ApplicationFiled: March 20, 2006Publication date: October 19, 2006Applicant: VIVUS, Inc.Inventor: Thomas Najarian
-
Publication number: 20060234951Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: ApplicationFiled: March 20, 2006Publication date: October 19, 2006Applicant: VIVUS, Inc.Inventor: Thomas Najarian
-
Publication number: 20060234952Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: ApplicationFiled: March 20, 2006Publication date: October 19, 2006Applicant: VIVUS, Inc.Inventor: Thomas Najarian
-
Patent number: 7056890Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: GrantFiled: June 3, 2003Date of Patent: June 6, 2006Assignee: VIVUS, Inc.Inventor: Thomas Najarian
-
Publication number: 20060041021Abstract: Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal potypeptide (VIP) and VIP agonists is administered to the vagina and/or vulvar region of the individual undergoing treatment. The formulations are also useful for improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. Pharmaceutical formulations and kits are also provided.Type: ApplicationFiled: October 28, 2005Publication date: February 23, 2006Applicant: Vivus, Inc.Inventors: Leland Wilson, Virgil Place
-
Publication number: 20050239742Abstract: A method is provided for treating a female individual who suffers from or is prone to dyspareunia. The method involves vaginal and/or vulvar administration of a formulation comprising a therapeutically effective amount of a carrageenan and a pharmaceutically acceptable aqueous carrier. In addition, a carrageenan-based formulation is provided as a new composition of matter. Packaged kits for an individual to use in the administration of a carrageenan-based formulation as provided as well.Type: ApplicationFiled: April 7, 2005Publication date: October 27, 2005Applicant: VIVUS, Inc.Inventors: Virgil Place, Leland Wilson
-
Patent number: 6946141Abstract: A method is provided for treatment of premature ejaculation by administration of an antidepressant drug selected from tricyclic antidepressants, tetracyclic antidepressants, MAO inhibitors, azaspirone antidepressants, and atypical non-SRI antidepressants. In a preferred embodiment, administration is on as “as-needed” basis, i.e., the drug is administered immediately or at most several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.Type: GrantFiled: November 21, 2001Date of Patent: September 20, 2005Assignee: Vivus, Inc.Inventors: Peter Tam, Neil Gesundheit, Leland F. Wilson
-
Publication number: 20050070516Abstract: A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves administration of a pharmaceutical formulation containing an effective amount of an androgenic agent, wherein administration is on an as-needed basis rather than involving chronic pharmacotherapy. Local delivery may be accomplished via administration to the vagina, vulvar area or urethra of the individual, although oral administration is preferred for those androgenic agents that are orally active. Formulations and kits for carrying out the method are provided as well.Type: ApplicationFiled: November 16, 2004Publication date: March 31, 2005Applicant: VIVUS INC.Inventors: Leland Wilson, Peter Tam
-
Patent number: 6593313Abstract: Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.Type: GrantFiled: July 13, 2001Date of Patent: July 15, 2003Assignee: Vivus, Inc.Inventors: Virgil A. Place, Leland F. Wilson, Paul C. Doherty, Jr., Mark S. Hanamoto, Alfred P. Spivack, Neil Gesundheit, Sean R. Bennett